Literature DB >> 18781825

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

Katrina MacAulay1, James R Woodgett.   

Abstract

BACKGROUND: In spite of its rather specific name, glycogen synthase kinase-3 (GSK-3) is an eclectic cellular regulator that modulates an array of processes from nuclear transcription, to neurological functions and metabolism. The enzyme is also a focal point for diverse signaling pathways that act to suppress its activity.
OBJECTIVES: To review recent evidence supporting the important role GSK-3 plays in glucose homeostasis and discuss the therapeutic potential of inhibiting this enzyme in the treatment of diabetes and insulin resistance. RESULTS/
CONCLUSION: Despite its pleiotropic nature, GSK-3 has significant promise as a target for diabetes due to functional partitioning of the enzyme, tissue-selectivity and acute dosage-dependency of effects of inhibition, suggesting useful therapeutic windows.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781825      PMCID: PMC4485462          DOI: 10.1517/14728222.12.10.1265

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  67 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

2.  Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3.

Authors:  C J Fiol; A M Mahrenholz; Y Wang; R W Roeske; P J Roach
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

3.  Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin.

Authors:  A Nagafuchi; M Takeichi
Journal:  Cell Regul       Date:  1989-11

4.  Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes.

Authors:  S J Oreña; A J Torchia; R S Garofalo
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

5.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.

Authors:  M J Hart; R de los Santos; I N Albert; B Rubinfeld; P Polakis
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

6.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.

Authors:  Sharon Amit; Ada Hatzubai; Yaara Birman; Jens S Andersen; Etti Ben-Shushan; Matthias Mann; Yinon Ben-Neriah; Irit Alkalay
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

Review 7.  Regulating insulin signaling and beta-cell function through IRS proteins.

Authors:  Morris F White
Journal:  Can J Physiol Pharmacol       Date:  2006-07       Impact factor: 2.273

Review 8.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

9.  Control of glycogen synthesis by glucose, glycogen, and insulin in cultured human muscle cells.

Authors:  R Halse; S M Bonavaud; J L Armstrong; J G McCormack; S J Yeaman
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

10.  Short-term in vitro inhibition of glycogen synthase kinase 3 potentiates insulin signaling in type I skeletal muscle of Zucker Diabetic Fatty rats.

Authors:  Erik J Henriksen; Mary K Teachey
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

View more
  41 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

2.  Development of a quantitative 96-well method to image glycogen storage in primary rat hepatocytes.

Authors:  James Pilling; Helen Garside; Edward Ainscow
Journal:  Mol Cell Biochem       Date:  2010-03-24       Impact factor: 3.396

3.  Improved insulin sensitivity with calorie restriction does not require reduced JNK1/2, p38, or ERK1/2 phosphorylation in skeletal muscle of 9-month-old rats.

Authors:  Naveen Sharma; Abhijit D Bhat; Anketse D Kassa; Yuanyuan Xiao; Edward B Arias; Gregory D Cartee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-19       Impact factor: 3.619

4.  Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.

Authors:  Valentina Di Caro; Antonella D'Anneo; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 5.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

Review 6.  Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.

Authors:  Anand Prakash Singh; Prachi Umbarkar; Yuanjun Guo; Thomas Force; Manisha Gupte; Hind Lal
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

7.  Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons.

Authors:  Lisa McGill-Vargas; Amalia Gastaldelli; Hanyu Liang; Diana Anzueto Guerra; Teresa Johnson-Pais; Steven Seidner; Donald McCurnin; Giovanna Muscogiuri; Ralph DeFronzo; Nicolas Musi; Cynthia Blanco
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

8.  The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.

Authors:  Mohammad A Khanfar; Bilal Abu Asal; Mudit Mudit; Amal Kaddoumi; Khalid A El Sayed
Journal:  Bioorg Med Chem       Date:  2009-06-27       Impact factor: 3.641

9.  Cardioprotection leads to novel changes in the mitochondrial proteome.

Authors:  Renee Wong; Angel M Aponte; Charles Steenbergen; Elizabeth Murphy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-23       Impact factor: 4.733

10.  Regulation of BMAL1 protein stability and circadian function by GSK3beta-mediated phosphorylation.

Authors:  Saurabh Sahar; Loredana Zocchi; Chisato Kinoshita; Emiliana Borrelli; Paolo Sassone-Corsi
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.